ClinicalTrials.gg
RecruitingNCT07805356RECLAIM-HPUpdated Nov 12, 2026

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

A Phase 3 interventional study of Encaleret and Placebo in Hypoparathyroidism and Chronic Hypoparathyroidism, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company. Recruiting at 10 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company (part of BridgeBio) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 12, 2026First site in JapanEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.

Planned enrollment
2nd of 34
160 · median 41
Started
2026
with 5 others
Phase 3
13 of 43
3 open now
Primary completion
2028-01
later than 5 of 11 live
Registered
43rd of 43
by date
Lead sponsor
3 of 43
Calcilytix Therapeutics, Inc., a BridgeBio company

Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 2nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 43rd registered.

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

Browse Hypoparathyroidism studies →

Open to participants now

8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hypoparathyroidism with a site in United States, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).

03

Conditions studied

  • Hypoparathyroidism
  • Chronic Hypoparathyroidism

Browse trials for

Keywords

  • Chronic Hypoparathyroidism
  • Hypoparathyroidism
  • Encaleret
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have had a clinically confirmed diagnosis of chronic HP, with disease duration of at least 26 weeks prior to screening. Cause of chronic HP can be postsurgical, , genetic, or idiopathic.
  • For participants with nonsurgical chronic HP etiology, sufficient documentation that the participant does not harbor any variants in calcium-sensing receptor (CASR) or GNA11 that are classified as pathogenic, likely pathogenic, or of uncertain significance, with the exception of benign common polymorphisms (CASR A986S and R990G) is needed.
  • Participants must be on stable doses of calcium and active vitamin D supplementation at or above the following minimum thresholds for at least 6 weeks prior to screening.

For participants enrolled in study sites outside Japan:

  • Calcitriol ≥0.5 micrograms (μg)/day or alfacalcidol ≥1.0 μg/day
  • Elemental calcium ≥800 milligrams (mg)/day (for example, calcium citrate, calcium carbonate)
  • Participants must meet the following criteria during screening: cCa within 7.8 to 9.5 mg/deciliter (dL) and 24-hour UCa ≥300 mg/day (males) or ≥250 mg/day (females).
  • Participants have serum 25-hydroxy (OH) vitamin D concentration of 20 to 80 nanograms (ng)/milliliter (mL) (50-200 nanomoles [nmol]/liter [L]).
  • Participants have serum magnesium concentration within the reference range.
  • Participants on thiazide or loop diuretics must be able to discontinue them during the first 24 weeks of study (treatment).
  • Participants must be capable of giving signed or assent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

Key Exclusion Criteria:

  • Genetically confirmed diagnosis of autosomal dominant hypocalcemia type 1 (ADH1) or autosomal dominant hypocalcemia type 2 (ADH2) due to activating variants in CASR or GNA11, respectively.
  • History of hypocalcemic seizure in the 3 months prior to screening.
  • History of cancer (except thyroid cancer, non-melanoma skin cancer) or bone in the 5 years prior to screening.
  • Prior skeletal irradiation, chemotherapy with alkylating agents, or diagnosis of Paget's disease, fibrous dysplasia, chronic osteomyelitis, bone infarcts, benign bone tumors with curettage and grafting, retinoblastoma, or Li-Fraumeni syndrome.
  • Presence or history of any disease or condition (for example, drug or alcohol dependence) that, in the view of the investigator, would affect the participant's safety or places the participant at high risk of poor treatment compliance or of not completing the study.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Encaleret

    Participants will receive encaleret during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label long-term extension (LTE) period to continue receiving encaleret for up to 192 weeks.

    Drug: Encaleret

  • Placebo comparator
    Placebo

    Participants will receive placebo during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label LTE period to receive encaleret for up to 192 weeks.

    Drug: Encaleret · Drug: Placebo

Interventions

  • Oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urine Calcium (UCa) Within the Protocol-defined Target Range

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With cCa Within Protocol-defined Range

    Time frame: Week 24

  2. Change From Baseline to Week 24 in cCa

    Time frame: Baseline, Week 24

  3. Absolute Value of cCa at Week 24

    Time frame: Week 24

  4. Number of Participants With 24-hour UCa Below the Sex-specific Upper Reference Limits (Protocol-defined Range)

    Time frame: Week 24

  5. Change from Baseline to Week 24 in 24-hour UCa

    Time frame: Baseline, Week 24

  6. Absolute Value of 24-hour UCa at Week 24

    Time frame: Week 24

  7. Number of Participants Who Meet the Primary Endpoint (Biochemical Response) and Have a Reduction From Baseline in Calcium Supplements Dose

    Time frame: Baseline up to Week 24

  8. Percent Change From Baseline to Week 24 in Daily Intake of Calcium Supplements Among the Participants Who Meet the Primary Endpoint (Biochemical Response)

    Time frame: Baseline, Week 24

  9. Number of Participants With Calcium Independence

    Time frame: Week 20 to Week 24

  10. Change from Baseline in Signs and Symptoms of Hypoparathyroidism, Based on Participants' Responses

    Time frame: Baseline, Week 24

  11. Number of Participants Who Meet the Primary Endpoint (Biochemical Response) and Have a Reduction From Baseline in Active Vitamin D Dose

    Time frame: Week 24

  12. Percent Change From Baseline in Daily Intake of Active Vitamin D Among the Participants Who Meet the Primary Endpoint (Biochemical Response)

    Time frame: Baseline, Week 24

  13. Number of Participants Who Meet the Primary Endpoint (Biochemical Response) and Has Active Vitamin D Independence

    Time frame: Week 24

  14. Number of Participants Who Meet Specific Protocol-defined Criteria or Calcium and Vitamin D Analysis

    Protocol-defined criteria which include the following: cCa within protocol-defined range, 24-hour UCa below the sex-specific upper reference limits (protocol-defined range), independence from conventional therapy, no increase in the study drug dose, and no missing active vitamin D and calcium supplementation data.

    Time frame: Week 20 to Week 24

07

Study locations

10 of 10 sites recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Boston, Massachusetts 02114, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Reno, Nevada 89511, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Greenville, North Carolina 27834, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Columbus, Ohio 43210, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    El Paso, Texas 79935, United States
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Oakville, Ontario L6M 1M1, Canada
    Recruiting
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
    Tokyo, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.

Of 15 phase 3 interventional studies under Hypoparathyroidism, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 86. This study's planned 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2033
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first site in Japan
Show 5 added (4 United States, 1 Japan)
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Indianapolis, United States
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Boston, United States
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Columbus, United States
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Philadelphia, United States
  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Tokyo, Japan
Nov 12, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedParticipants must have had a clinically confirmed diagnosis of chronic HP, with disease duration of at least 26 weeks prior to screening. Cause of chronic HP can be postsurgical, autoimmune, genetic, or idiopathic.
  • EditedHistory of cancer (except thyroid cancer, non-melanoma skin cancer) or bone metastases in the 5 years prior to screening.
Nov 4, 2026
Show all 2 updates
  1. Nov 12, 2026
    5 sites added — first site in Japan
    Show 5 added (4 United States, 1 Japan)
    • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Indianapolis, United States
    • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Boston, United States
    • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Columbus, United States
    • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Philadelphia, United States
    • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site · Tokyo, Japan
  2. Nov 4, 2026
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedParticipants must have had a clinically confirmed diagnosis of chronic HP, with disease duration of at least 26 weeks prior to screening. Cause of chronic HP can be postsurgical, autoimmune, genetic, or idiopathic.
    • EditedHistory of cancer (except thyroid cancer, non-melanoma skin cancer) or bone metastases in the 5 years prior to screening.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07805356
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Aug 31, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2033 (estimated)
Last update
Nov 12, 2026

Study contacts

Medical Information
Contact
MedInfo@bridgebio.com
650-600-3610
Calcilytix Medical Director
study director · Calcilytix Therapeutics, Inc., a BridgeBio company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Encaleret

Start the discussion